UA68327C2 - A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals - Google Patents
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals Download PDFInfo
- Publication number
- UA68327C2 UA68327C2 UA97126424A UA97126424A UA68327C2 UA 68327 C2 UA68327 C2 UA 68327C2 UA 97126424 A UA97126424 A UA 97126424A UA 97126424 A UA97126424 A UA 97126424A UA 68327 C2 UA68327 C2 UA 68327C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mma
- virus
- recombinant
- gene
- fact
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 175
- 229960005486 vaccine Drugs 0.000 title claims abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- 210000004027 cell Anatomy 0.000 title claims description 103
- 238000000034 method Methods 0.000 title claims description 26
- 241001465754 Metazoa Species 0.000 title claims description 17
- 210000003527 eukaryotic cell Anatomy 0.000 title claims description 13
- 230000003053 immunization Effects 0.000 title claims description 7
- 238000002649 immunization Methods 0.000 title claims description 6
- 238000000338 in vitro Methods 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 136
- 238000012217 deletion Methods 0.000 claims abstract description 35
- 230000037430 deletion Effects 0.000 claims abstract description 34
- 239000013603 viral vector Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 37
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 36
- 230000003612 virological effect Effects 0.000 claims description 34
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 241000700626 Cowpox virus Species 0.000 claims description 17
- 230000000890 antigenic effect Effects 0.000 claims description 17
- 230000001177 retroviral effect Effects 0.000 claims description 16
- 239000013604 expression vector Substances 0.000 claims description 15
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 15
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims description 13
- 238000010276 construction Methods 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 13
- 238000011081 inoculation Methods 0.000 claims description 9
- 238000002955 isolation Methods 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- 108700005077 Viral Genes Proteins 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 230000003362 replicative effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 5
- 239000013612 plasmid Substances 0.000 description 41
- 241000700618 Vaccinia virus Species 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000012634 fragment Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 10
- 239000003155 DNA primer Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 244000068988 Glycine max Species 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- 101710137500 T7 RNA polymerase Proteins 0.000 description 8
- 108020005202 Viral DNA Proteins 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 7
- 108020001019 DNA Primers Proteins 0.000 description 7
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 4
- 241000700629 Orthopoxvirus Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- -1 for example Proteins 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000721701 Lynx Species 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000003740 cowpox Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- LJQDDVJEZIEHNY-YIMUCPRWSA-N (4r)-4-[(5r,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-n,n-dimethylpentan-1-amine Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCCN(C)C)C)[C@@]2(C)CC1 LJQDDVJEZIEHNY-YIMUCPRWSA-N 0.000 description 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100043709 Mus musculus Stradb gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150021183 65 gene Proteins 0.000 description 1
- 101150046633 77 gene Proteins 0.000 description 1
- 101150068622 ATI gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010040864 CERE Proteins 0.000 description 1
- 101100001231 Caenorhabditis elegans aha-1 gene Proteins 0.000 description 1
- 101100366936 Caenorhabditis elegans sto-3 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000725630 Ectromelia virus Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101150004367 Il4i1 gene Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000018242 Obba <basidiomycete fungus> Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 101100047768 Rattus norvegicus Tspan31 gene Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001435321 Staphylococcus virus 77 Species 0.000 description 1
- 101150015964 Strn gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000587120 Vaccinia virus Ankara Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 101150070926 ct gene Proteins 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK78295 | 1995-07-04 | ||
PCT/EP1996/002926 WO1997002355A1 (en) | 1995-07-04 | 1996-07-03 | Recombinant mva virus, and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
UA68327C2 true UA68327C2 (en) | 2004-08-16 |
Family
ID=8097499
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA97126424A UA68327C2 (en) | 1995-07-04 | 1996-03-07 | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
UA20031212892A UA75411C2 (en) | 1995-07-04 | 1996-07-03 | Recombinant virus of mva |
UA20031212890A UA75410C2 (en) | 1995-07-04 | 1996-07-03 | Recombinant virus mva and use thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA20031212892A UA75411C2 (en) | 1995-07-04 | 1996-07-03 | Recombinant virus of mva |
UA20031212890A UA75410C2 (en) | 1995-07-04 | 1996-07-03 | Recombinant virus mva and use thereof |
Country Status (27)
Country | Link |
---|---|
US (6) | US6440422B1 (de) |
EP (3) | EP1312678B1 (de) |
JP (3) | JP4312260B2 (de) |
KR (1) | KR19990028617A (de) |
CN (3) | CN1554764B (de) |
AT (3) | ATE239796T1 (de) |
AU (1) | AU721735B2 (de) |
BR (1) | BR9609303B8 (de) |
CA (3) | CA2596274C (de) |
CZ (1) | CZ292460B6 (de) |
DE (3) | DE69635173T2 (de) |
DK (3) | DK1312679T3 (de) |
EE (3) | EE05138B1 (de) |
ES (3) | ES2199294T3 (de) |
HK (2) | HK1009830A1 (de) |
HU (2) | HU229261B1 (de) |
IL (5) | IL122120A (de) |
MX (1) | MX9800025A (de) |
NO (1) | NO322476B1 (de) |
NZ (1) | NZ313597A (de) |
PL (1) | PL186857B1 (de) |
PT (1) | PT836648E (de) |
RU (1) | RU2198217C2 (de) |
SI (3) | SI1312678T1 (de) |
TW (2) | TW575664B (de) |
UA (3) | UA68327C2 (de) |
WO (1) | WO1997002355A1 (de) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US7118754B1 (en) * | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
AU4556597A (en) * | 1996-09-24 | 1998-04-17 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
MY119381A (en) * | 1996-12-24 | 2005-05-31 | Gsf Forschungszentrum Umwelt | Recombinant mva virus, and the use thereof |
US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
FR2784997A1 (fr) * | 1998-10-22 | 2000-04-28 | Transgene Sa | Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes |
US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
US6682742B1 (en) | 1999-05-28 | 2004-01-27 | Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh | Vector for integration of heterologous sequences into poxviral genomes |
US20150231227A1 (en) * | 2000-03-02 | 2015-08-20 | Emory University | Compositions and methods for generating an immune response |
PL205922B1 (pl) | 2000-03-14 | 2010-06-30 | Bavarian Nordic As | Zmodyfikowany wirus Ankara (MVA), zakażona nim komórka gospodarza, jego zastosowania, kompozycja farmaceutyczna i sposoby otrzymywania wirusa oraz sekwencji kwasu nukleinowego, peptydu i/lub polipeptydu |
DE10042598A1 (de) * | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
AU2002211654A1 (en) * | 2000-10-10 | 2002-04-22 | Genstar Therapeutics | Minimal adenoviral vector and recombinant vaccines based thereon |
DK1335987T4 (en) * | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7740863B2 (en) | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
DE10144664B4 (de) * | 2001-09-11 | 2005-06-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
SI1407006T1 (sl) | 2001-12-20 | 2006-04-30 | Bavarian Nordic As | Postopek za ponovno pridobivanje in ciscenje poksvirusov iz inficiranih celic |
DE60314823T3 (de) | 2002-04-19 | 2017-11-16 | Bavarian Nordic A/S | Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene |
US20060029619A1 (en) * | 2002-05-16 | 2006-02-09 | Paul Howley | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter |
DE60303218T2 (de) | 2002-05-16 | 2006-09-14 | Bavarian Nordic A/S | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
ATE393212T2 (de) | 2002-09-05 | 2008-05-15 | Bavarian Nordic As | Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen |
DE10249390A1 (de) * | 2002-10-23 | 2004-05-13 | Ruprecht-Karls-Universität Heidelberg | Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria |
EP1567653B1 (de) * | 2002-11-25 | 2007-06-20 | Bavarian Nordic A/S | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
JP4686443B2 (ja) * | 2003-02-18 | 2011-05-25 | ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー | 組換えmvaおよびその生産方法 |
JP5052893B2 (ja) | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
EP1606411B1 (de) | 2003-03-27 | 2008-12-10 | Ottawa Health Research Institute | Mutante vesicular stomatitis viren und deren verwendungen |
US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
US20100189747A1 (en) * | 2003-07-31 | 2010-07-29 | Raymond Weinstein | Compositions and methods for treating or preventing hiv infection |
EP1518932A1 (de) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Mutierte Form des Modifizierten Vaccinia Virus Ankara (MVA) sowie ihre Verwendung |
DE602004009743T2 (de) | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara |
JP4719855B2 (ja) | 2003-12-05 | 2011-07-06 | 国立大学法人北海道大学 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
EP1683870A1 (de) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Auf die Verwendung von MVA basierte Impfstoffe |
US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
BRPI0712158B8 (pt) * | 2006-06-20 | 2021-05-25 | Transgene Sa | processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada |
WO2008076157A2 (en) * | 2006-09-08 | 2008-06-26 | Duke University | Modified vaccinia ankara virus vaccine |
EP2064229B1 (de) | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Onkolytisches rhabdovirus |
JP5964540B2 (ja) | 2006-10-06 | 2016-08-03 | バヴァリアン・ノルディック・アクティーゼルスカブ | Mvaを使ってがんを処置する方法 |
US20080241139A1 (en) * | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
US8557764B2 (en) * | 2007-01-26 | 2013-10-15 | The Regents Of The University Of Colorado, A Body Corporate | Methods of modulating immune function |
DK2152736T3 (en) | 2007-05-03 | 2017-09-18 | Lysomab Gmbh | Complement factor H-derived short-consensus repeat (SCR) antibody constructs |
AU2008250596C1 (en) * | 2007-05-14 | 2010-11-25 | Bavarian Nordic A/S | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US8003363B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US20100285050A1 (en) * | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
BRPI0800485B8 (pt) * | 2008-01-17 | 2021-05-25 | Univ Minas Gerais | vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose |
JP2011511640A (ja) | 2008-02-12 | 2011-04-14 | サノフィ パストゥール リミテッド | ポックス・ウイルスの精製方法 |
US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
US9670506B2 (en) | 2009-04-30 | 2017-06-06 | Consejo Superior De Investigaciones Cientificas | Modified immunization vectors |
CA2770075C (en) * | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
US9005632B2 (en) | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
WO2011063359A1 (en) * | 2009-11-20 | 2011-05-26 | Inviragen, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
EP2668201A2 (de) | 2011-01-28 | 2013-12-04 | Sanofi Pasteur SA | Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten |
WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
AU2012294606B2 (en) | 2011-08-05 | 2016-10-06 | Sillajen Biotherapeutics, Inc. | Methods and compositions for production of vaccinia virus |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
WO2013046034A2 (en) * | 2011-09-26 | 2013-04-04 | Theravectys | Use of non-subtype b gag proteins for lentiviral packaging |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
EP2620446A1 (de) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogene zur HIV-Impfung |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
EA029492B1 (ru) | 2012-07-10 | 2018-04-30 | Трансген Са | Вакцина на основе микобактериальных антигенов |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3092000A1 (de) | 2014-01-09 | 2016-11-16 | Transgene SA | Fusion von heterooligomeren mycobakteriellen antigenen |
GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
WO2016115116A1 (en) | 2015-01-12 | 2016-07-21 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
HUE055916T2 (hu) | 2015-12-15 | 2021-12-28 | Janssen Vaccines & Prevention Bv | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szóló eljárások |
ES2944314T3 (es) | 2016-01-08 | 2023-06-20 | Geovax Inc | Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor |
US20190030157A1 (en) | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
WO2017147554A2 (en) * | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
CN109219448B (zh) | 2016-06-16 | 2022-09-20 | 扬森疫苗与预防公司 | Hiv疫苗配制品 |
EP3506937A1 (de) | 2016-09-02 | 2019-07-10 | Janssen Vaccines & Prevention B.V. | Verfahren zur induzierung einer immunreaktion gegen hiv-infektionen bei patienten während einer antiretroviralen therapie |
EA201990715A1 (ru) | 2016-09-15 | 2019-08-30 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
CN110958887B (zh) | 2017-06-15 | 2023-10-31 | 扬森疫苗与预防公司 | 编码hiv抗原的痘病毒载体及其使用方法 |
CN111065406A (zh) | 2017-06-21 | 2020-04-24 | 特兰斯吉恩股份有限公司 | 个性化疫苗 |
KR20200031655A (ko) | 2017-07-19 | 2020-03-24 | 얀센 백신스 앤드 프리벤션 비.브이. | 삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이 |
US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CN114901297A (zh) * | 2019-10-16 | 2022-08-12 | 卡利威尔免疫治疗公司 | 用于原位产生逆转录病毒的生产者病毒 |
BR112022009421A2 (pt) | 2019-11-14 | 2022-10-25 | Aelix Therapeutics S L | Regimes de dosagem para vacinas |
EP3842065A1 (de) | 2019-12-23 | 2021-06-30 | Transgene | Verfahren zum entwurf eines rekombinanten pockenvirus für einen therapeutischen impfstoff |
EP3928789A1 (de) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene |
WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
KR20240004764A (ko) | 2021-04-30 | 2024-01-11 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 mhc 발현을 위한 종양용해성 바이러스 |
WO2022269003A1 (en) | 2021-06-23 | 2022-12-29 | Consejo Superior De Investigaciones Cientificas | MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN |
EP4108257A1 (de) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert |
WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
US20230364227A1 (en) | 2022-05-12 | 2023-11-16 | Pellis Therapeutics, Inc. | Poxvirus adjuvant for t-cell vaccination |
EP4316514A1 (de) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
JPH0795954B2 (ja) | 1982-11-30 | 1995-10-18 | アメリカ合衆国 | 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法 |
US5679511A (en) * | 1986-10-06 | 1997-10-21 | Donald Guthrie Foundation For Medical Research, Inc. | CDNA clones for a regulatory protein in the melanin-production pathway |
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
CN1042564A (zh) * | 1988-11-11 | 1990-05-30 | 中国科学院上海生物化学研究所 | 乙肝疫苗的制备方法及其制品 |
JPH03271233A (ja) | 1990-03-19 | 1991-12-03 | Inst Pasteur | ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発 |
EP0613378A1 (de) | 1991-10-28 | 1994-09-07 | Institut Pasteur | Induzierung von schützen gegen virale infektionen durch die synergie zwischen virale proteine und virale peptide |
DK1025849T5 (da) * | 1992-12-22 | 2003-02-24 | Ludwig Inst Cancer Res | Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5756666A (en) * | 1993-10-19 | 1998-05-26 | Ajinomoto Co., Inc. | Peptides capable of inducing immune response to HIV |
US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
-
1996
- 1996-03-07 UA UA97126424A patent/UA68327C2/uk unknown
- 1996-07-03 CN CN2004100367144A patent/CN1554764B/zh not_active Expired - Lifetime
- 1996-07-03 EE EEP200300331A patent/EE05138B1/xx unknown
- 1996-07-03 CN CNA2005101248556A patent/CN1782071A/zh active Pending
- 1996-07-03 AU AU66110/96A patent/AU721735B2/en not_active Expired
- 1996-07-03 CN CNB961952547A patent/CN1154742C/zh not_active Expired - Lifetime
- 1996-07-03 DE DE69635173T patent/DE69635173T2/de not_active Expired - Lifetime
- 1996-07-03 UA UA20031212892A patent/UA75411C2/uk unknown
- 1996-07-03 EP EP03001378A patent/EP1312678B1/de not_active Expired - Lifetime
- 1996-07-03 BR BRPI9609303-0B8A patent/BR9609303B8/pt active IP Right Grant
- 1996-07-03 CZ CZ19974241A patent/CZ292460B6/cs not_active IP Right Cessation
- 1996-07-03 IL IL12212096A patent/IL122120A/xx not_active IP Right Cessation
- 1996-07-03 AT AT96925654T patent/ATE239796T1/de active
- 1996-07-03 CA CA2596274A patent/CA2596274C/en not_active Expired - Lifetime
- 1996-07-03 EE EE9700344A patent/EE04199B1/xx unknown
- 1996-07-03 DE DE69635172T patent/DE69635172T2/de not_active Expired - Lifetime
- 1996-07-03 EP EP03001379A patent/EP1312679B8/de not_active Expired - Lifetime
- 1996-07-03 ES ES96925654T patent/ES2199294T3/es not_active Expired - Lifetime
- 1996-07-03 DK DK03001379T patent/DK1312679T3/da active
- 1996-07-03 ES ES03001378T patent/ES2249647T3/es not_active Expired - Lifetime
- 1996-07-03 WO PCT/EP1996/002926 patent/WO1997002355A1/en active Application Filing
- 1996-07-03 JP JP50482497A patent/JP4312260B2/ja not_active Expired - Lifetime
- 1996-07-03 HU HU0402350A patent/HU229261B1/hu unknown
- 1996-07-03 SI SI9630718T patent/SI1312678T1/sl unknown
- 1996-07-03 DK DK96925654T patent/DK0836648T3/da active
- 1996-07-03 CA CA002225278A patent/CA2225278C/en not_active Expired - Lifetime
- 1996-07-03 PL PL96324347A patent/PL186857B1/pl unknown
- 1996-07-03 NZ NZ313597A patent/NZ313597A/xx not_active IP Right Cessation
- 1996-07-03 HU HU9802217A patent/HU224061B1/hu active IP Right Grant
- 1996-07-03 SI SI9630719T patent/SI1312679T1/sl unknown
- 1996-07-03 RU RU98101904/13A patent/RU2198217C2/ru active
- 1996-07-03 PT PT96925654T patent/PT836648E/pt unknown
- 1996-07-03 AT AT03001379T patent/ATE304058T1/de active
- 1996-07-03 EP EP96925654A patent/EP0836648B1/de not_active Expired - Lifetime
- 1996-07-03 DE DE69628011T patent/DE69628011T2/de not_active Expired - Lifetime
- 1996-07-03 DK DK03001378T patent/DK1312678T3/da active
- 1996-07-03 SI SI9630623T patent/SI0836648T1/xx unknown
- 1996-07-03 CA CA2608864A patent/CA2608864C/en not_active Expired - Lifetime
- 1996-07-03 ES ES03001379T patent/ES2249648T3/es not_active Expired - Lifetime
- 1996-07-03 AT AT03001378T patent/ATE304057T1/de active
- 1996-07-03 KR KR1019970709939A patent/KR19990028617A/ko not_active Application Discontinuation
- 1996-07-03 MX MX9800025A patent/MX9800025A/es unknown
- 1996-07-03 EE EEP200300332A patent/EE04753B1/xx unknown
- 1996-07-03 UA UA20031212890A patent/UA75410C2/uk unknown
- 1996-12-31 TW TW085116379A patent/TW575664B/zh not_active IP Right Cessation
- 1996-12-31 TW TW092116681A patent/TWI245075B/zh not_active IP Right Cessation
-
1998
- 1998-01-02 NO NO19980026A patent/NO322476B1/no not_active IP Right Cessation
- 1998-01-02 US US09/002,443 patent/US6440422B1/en not_active Expired - Lifetime
- 1998-09-15 HK HK98110632A patent/HK1009830A1/xx not_active IP Right Cessation
-
2002
- 2002-05-15 US US10/147,284 patent/US7198934B2/en not_active Expired - Fee Related
-
2004
- 2004-09-28 IL IL164318A patent/IL164318A/en not_active IP Right Cessation
-
2005
- 2005-01-11 HK HK05100216.3A patent/HK1068015A1/xx not_active IP Right Cessation
-
2006
- 2006-09-19 US US11/523,030 patent/US20070071770A1/en not_active Abandoned
- 2006-09-19 US US11/522,889 patent/US8153138B2/en not_active Expired - Fee Related
- 2006-09-19 US US11/523,004 patent/US20070071769A1/en not_active Abandoned
-
2007
- 2007-03-12 JP JP2007062630A patent/JP4764366B2/ja not_active Expired - Lifetime
- 2007-03-12 JP JP2007062631A patent/JP4764367B2/ja not_active Expired - Lifetime
-
2009
- 2009-12-01 IL IL202448A patent/IL202448A0/en unknown
-
2010
- 2010-06-14 US US12/814,602 patent/US8197825B2/en not_active Expired - Fee Related
-
2011
- 2011-05-17 IL IL212933A patent/IL212933A0/en unknown
-
2012
- 2012-05-02 IL IL219528A patent/IL219528A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA68327C2 (en) | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals | |
NZ227562A (en) | Recombinant vaccinia virus (mva) containing a dna insert coding for a foreign antigen | |
US20060002896A1 (en) | Method of generating recombinant MVA | |
ES2380731T3 (es) | Vacunas basadas en el uso de VMA |